Clinical Trials Logo

Clinical Trial Summary

This is a first-in-human, single-center, single-blinded, observer-masked randomized, dose escalation (two doses), placebo-controlled study in healthy volunteers.


Clinical Trial Description

Subjects will be assigned to one of two cohorts.

1. Cohort 1 will receive the lower dose of 2 μg vaccine (with or without alum adjuvant) or matching placebo.

2. Cohort 2 will receive the higher dose of 10 μg vaccine (with or without alum adjuvant) or matching placebo.

Eligible subjects will be randomized to receive the 2 μg dose or 10 µg without or with alum or matching placebo, at a ratio of 3:1, as three single IM injections. There will be an interval of 28(±3) days) between each treatment.

The study will be conducted in a stepwise approach in which a "Pioneer" Group of 2 subjects (one receiving the active vaccine and one receiving the matching placebo) will receive the first injection. These subjects will remain in-house for a 24-hours medical observation after the first injection (not required in the subsequent injections) Once it has been established that there are no safety concerns in the non-adjuvanted "Pioneer" Groups (and after no less than 48 hrs), the next "Pioneer" group (one subject receiving adjuvanted 2 μg vaccine and one receiving the matching alum placebo) will be injected.

If no safety concerns are raised in this group also, after no less than 48 hrs, the rest of the subjects may receive the first injection. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02797236
Study type Interventional
Source Institut Pasteur
Contact
Status Completed
Phase Phase 1
Start date September 2016
Completion date December 2017

See also
  Status Clinical Trial Phase
Completed NCT04056117 - A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants Phase 1/Phase 2
Completed NCT02445963 - Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Phase 1
Not yet recruiting NCT05961059 - InvaplexAR-Detox and dmLT Adjuvant in the Netherlands and Zambia Phase 1
Completed NCT00485134 - Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection Phase 1/Phase 2
Completed NCT01369927 - Shigella Sonnel O-SPC/rBRU Conjugate Vaccine Phase 1
Completed NCT02034500 - Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults Phase 1
Completed NCT01509846 - Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults Phase 1
Not yet recruiting NCT05959616 - Shigella Sonnei 53G Human Infection Study in Kenyan Adults Phase 1
Completed NCT02105714 - Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders N/A
Withdrawn NCT01399424 - Shigella Sonnei OSPC-rDT Conjugate Vaccine Phase 1
Completed NCT00800930 - Therapeutic Induction of Endogenous Antibiotics Phase 2
Completed NCT00368316 - Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel Phase 3
Recruiting NCT05182749 - Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis Phase 1/Phase 2
Completed NCT02388009 - Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a Phase 1
Completed NCT02017899 - A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults. Phase 1
Completed NCT01069471 - Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella Phase 1
Completed NCT02646371 - Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a Phase 2
Recruiting NCT05156528 - Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years Phase 3
Completed NCT03854929 - Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery Phase 4
Recruiting NCT05121974 - Tebipenem Trial in Children With Shigellosis Phase 2